

Biotech investing: Is there a doctor in the house?

60 seconds with the portfolio manager

APRIL 2025

This marketing communication is intended for non-professional investors.



Servags Michielssens

PhD, CFA, Head of Healthcare, Thematic Global Equity



Linden Thomson

CFA, Senior Portfolio Manager

Servaas Michielssens and Linden Thomson answer investors' questions about a sector where deep specialist knowledge is essential for consistent stock selection success.

What are the key drivers to the performance of the biotech sector?

Biotech can be considered the innovation engine of the biopharma and drug sector, often sitting at the cutting edge of the next medical breakthrough. Over time, the distinction between pharmaceuticals and biotechnology has blurred, as pharmaceutical companies have acquired traditional biotech firms and their technologies. Today, most of the top 10 best-selling drugs globally are biotech-derived.

The biotech sector is characterized by high growth, innovation-driven developments, and structural support from demographic shifts. It also offers defensive commercial business investment opportunities, making it a compelling sector for long-term investors.

What does this mean for investors?

Despite its crucial role in healthcare innovation, biotech remains underrepresented in broad market indices. Traditional biotech companies make up less than 10% of the MSCI World Healthcare index and an even smaller proportion of the MSCI World index⁽¹⁾. As a result, investors do not gain significant exposure to this sector through broader generalist US strategies.

This underrepresentation, combined with the unique characteristics of the biotech industry, creates a compelling case for active stock selection. The sector's reliance on Research & Development ("R&D") pipelines leads to significant dispersion in share prices, making biotech a stockpickers' market. Over time, biotech share prices tend to correlate with revenue and sales growth. As such, we continue to focus on material commercial opportunities.

Beyond individual stock opportunities, the broader biopharma sector has demonstrated its value over the last 5-10 years, transforming the outlook for patients with various cancers and bringing Covid-19 vaccines to market in record time.

60 SECONDS
WITH THE FUND MANAGER

(1) Source: Candriam

PRE-CLINICAL /

- Needs to be positive for a drug to be authorized for human testing
- At this stage, failure risk is still high (80-90%)

PHASE I

 The safety of the product is assessed on healthy volunteers or in uncontrolled patient groups

 \rightarrow

 Failure risk still very high, even after promising data

PHASE II

Optimal dosing is determined, providing a first indication of efficacy (20-400 patients)

PHASE III

- Well-controlled studies of established dose in thousands of patients.
- The failure risk of an individual drug is greatly reduced after a successful Phase III.

Looking ahead, we remain focused on breakthrough medical innovations that will impact patients across the multiple disease areas, including neurology and CNS (Central Nervous System), oncology, rare diseases, cardiometabolic conditions and more. At the same time, M&A activity continues to be a tailwind for equity performance in the biotechnology sector as large cap biotherapeutic companies continue to use this as a way to bolster R&D pipelines with quality innovation.

 \rightarrow

When is the right stage of drug development to invest in biotechs?

The ideal timing for investing in biotech varies with each investment opportunity. Early-stage drug development investments may offer yield significant returns but come with higher risk. Later-stage of development have a higher probability of success but often come with lower potential returns. Additionally, strong investment opportunities exist in companies with alreadyapproved drugs where clinical launches are expected to exceed commercial expectations.

Moreover, how these companies preform within the macroeconomic environment varies, requiring careful consideration in portfolio composition. We aim to build a balanced portfolio of highconviction, quality biotech companies.

 \rightarrow

What does successful stock picking in the biotechnology sector involve?

To be a successful biotech investor, one must evaluate three critical factors: science, company management team, and valuation:

- Understanding the science: it's essential. Investors must think like doctors analyzing clinical data in the context of patient impact, and the competitive landscape.
- Assessing management teams: drug development is rarely straightforward. A driven, transparent, and experienced management team significantly enhances the likelihood of success.
- Valuation and market dynamics: it is vital to accurately value the opportunity and make investments at the right price. To truly excel, an investor must also understand market dynamics. While valuations are largely objective, the recognition of value depends on market cycles. The convergence between intrinsic value and stock market price can sometimes take a long time. In risk-off environments, early-stage assets may be undervalued, while cash-generative biotech may gain favor. Navigating these cycles is key to long-term success.

What differentiates Candriam in mastering the inherent scientific complexity of this sector?

Mastering biotech investing requires deep scientific knowledge, financial expertise, and industry experience. At Candriam, our team brings nearly a century of combined expertise across scientific research, industry, and finance. Contrary to common intuition, the results of clinical trials are rarely straightforward or binary—they often require nuanced shades of interpretation. Analyzing this data demands a profound understanding of

disease contexts, which our healthcare team has developed over many years.

Additionally, translating this knowledge into valuation is a craft that requires extensive experience. Our team comprises six professionals, including four PhD holders, five with scientific degrees, and two Chartered Financial Analysts (CFAs). This multidisciplinary expertise allows us to navigate the complexities of biotech investing with confidence, positioning us to capture the transformative potential of medical innovation.

The main risks of the strategy are:


• Risk of capital loss:

There is no guarantee for investors relating to the capital invested in the strategy in question, and investors may not receive back the full amount invested.

• Equity risk:

Some strategies may be exposed to equity market risk through direct investment (through transferable securities and/or derivative products). These investments, which generate long or short exposure, may entail a risk of substantial losses. A variation in the equity market in the reverse direction to the positions can lead to the risk of losses and may cause the performance to fall.

The risks listed are not exhaustive, and further details on risks are available in regulatory documents.



This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval. Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value (*NAV) of the funds. This information is available either in English or in local languages for each country where the fund's marketing is approved.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change. In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.